Immutep's Eftilagimod Alfa Gains FDA Orphan Drug Status for Soft Tissue Sarcoma
Event summary
- FDA granted Orphan Drug Designation to eftilagimod alfa for treating soft tissue sarcoma (STS), a rare cancer.
- Designation follows Phase II EFTISARC-NEO trial success, showing 51.5% median tumor hyalinization/fibrosis in 38 patients.
- Eftilagimod alfa combined with radiotherapy and KEYTRUDA® met primary endpoint, exceeding historical benchmarks.
- Immutep is reviewing Phase III TACTI-004 trial discontinuation and considering late-stage STS study.
The big picture
The FDA’s Orphan Drug Designation for eftilagimod alfa underscores the growing focus on rare cancer treatments, particularly in immunotherapies. Immutep’s success in the EFTISARC-NEO trial highlights the potential of combination therapies in neoadjuvant settings, a trend gaining traction in oncology. The strategic pivot to STS could position Immutep as a key player in a niche but high-need market.
What we're watching
- Regulatory Advantage
- How FDA’s Orphan Drug Designation will accelerate eftilagimod alfa’s path to market exclusivity.
- Clinical Strategy
- Whether Immutep will prioritize STS over other indications following TACTI-004 trial review.
- Commercial Potential
- The pace at which Immutep can secure partnerships for late-stage STS trials.
Related topics